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MSn experiments involving low energy collisionally activated dissociation (CAD) in a
quadrupole ion trap were used to characterize the fragmentation of alkali, alkaline earth and
transition metal complexes of five cyclic peptides, and the results were compared with those
obtained for protonated cyclic peptides. Complexes with metal ions produced enhanced
abundances of the most diagnostic fragments for elucidating the primary structures. For
cyclosporin A, nickel and lithium complexes gave additional sequence information compared
with the protonated peptide. For depsipeptides, sodium and lead complexes were superior to
the protonated peptide or other metal complexes for sequencing residues, and CAD of the lead
complexes led to preferential cleavage of two residues at a time. For cyclic lipopeptides,
complexes with silver, nickel and strontium ions provided enhanced abundances of key
fragment ions. (J Am Soc Mass Spectrom 2004, 15, 1039–1054) © 2004 American Society for
Mass SpectrometryCyclic peptides are an important class of antibiot-ics that have been isolated from bacteria, fungi,and plants or prepared by synthetic methods
[1–3]. New cyclic peptide antibiotics are being synthe-
sized and discovered on a regular basis and have been
found to have numerous pharmaceutical applications
including their use as enzyme inhibitors, antifungal and
antibacterial agents, and immunosuppresion and anti-
cancer drugs [1–8]. This ongoing interest in biologically
active cyclic peptides has been supported by the use of
advanced analytical methods which are needed to char-
acterize the cyclic structures, many of which contain
modified amino acids.
The development of fast peptide and protein se-
quencing methods using tandem mass spectrometry
has been most beneficial for structural identification of
linear peptides and proteins [9–11]. The characteriza-
tion of cyclic peptides by mass spectrometry poses a
great analytical challenge because they don’t have well-
defined termini, as do linear peptides, which can be
used unambiguously to anchor the assignment of the
sequence of amino acids in an orderly fashion. More-
over, losses of amino acid residues must involve cleav-
age of two bonds of the peptide backbone, as opposed
to only one cleavage for linear peptides. In addition, the
ring-opening may occur at several backbone positions,
meaning that all the fragment ions are not referenced to
a single “terminal” position. One approach to expedite
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data is to use fragmentation databases or sophisticated
algorithms to suggest possible sequence matches, as is
done routinely for linear peptides and proteins [12–15].
Another approach is to increase the dimensionality of
the mass spectral data via MSn experiments until the
identity of the peptide or its sequence is satisfactorily
determined.
The first collisionally activated dissociation (CAD)
studies of protonated cyclic peptides were published in
the early 1980s by Gross et al. [16] and Aubagnac et al.
[17], and the work up to 1994 has been reviewed by
Eckart [18]. Since then, groups have reported CAD and
MSn results for protonated synthetic and naturally
occurring cyclic peptides [19–30].
Another approach to obtaining sequence informa-
tion for cyclic peptides relies on alternative ionization
methods rather than conventional protonation in order
to improve the quality of diagnostic CAD and MSn data.
Metal complexation has become one option for produc-
tion of ions by ESI [31, 32]. A few CAD studies have
been undertaken for metal complexes of cyclic peptides
and depsipeptides [33–37], the latter having alternating
amide and ester backbone bonds. Ngoka and Gross
studied the fragmentation of two cyclic pentapeptides,
cyclo(D-Trp-D-Asp-ProD-Val-Leu) and cyclo(D-Trp-D-
Asp-Pro-D-Ile-Leu), complexed with lithium and so-
dium ions [33]. It was found that metal cationized cyclic
peptides appear to usually undergo “charge remote”
fragmentation in which successive MSn cleavages did
not continuously move the apparent position of the
metal ion [33]. Gross and co-workers also investigated
valinomycin/lithium complexes [34] and sodium com-r Inc. Received January 16, 2004
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and enniatin B1 [35]. Cotter and co-workers undertook
low energy MSn experiments of sodium complexes of
nine cyclic hexapeptides [36]. Hue and coworkers stud-
ied the sodium complexes of the octapeptide surfactin
[37]. These few studies have demonstrated superior or
complementary sequencing data for the metal com-
plexes compared with protonated cyclic peptides.
Several other studies have examined the dissociation
patterns of metal-cationized linear peptides [38–50],
thus solidifying the merits of considering metal compl-
exation as an alternative to protonation for structural
characterization of peptides. These studies have shown
that the metal cation may bind at the C-terminus,
N-terminus, or at an interior residue depending on the
metal ion and the peptide sequence. Fragmentation
tended to be much more specific for the metal com-
plexes, with the metal ion directing cleavage at a certain
residue or terminus (e.g., arginine for silver, histidine
for divalent transition metals, and the C-terminus for
copper). To our knowledge, no studies have previously
reported the comparison of CAD of alkali, alkaline
earth, and transition metal ion complexes of cyclic
peptides to protonated cyclic peptides.
The present work focuses on the use of CAD and
MSn experiments of protonated and metal-cationized
cyclic peptides formed by ESI and analyzed in a quad-
rupole ion trap mass spectrometer. The cyclic peptides
studied ranged in size from six to twelve residues and
included cyclosporin A (Figure 1a), the two depsipep-
tides, valinomycin and enniantin A (Figures 1b and c),
Figure 1. Structures of (a) cyclosporin A and1and the lipopeptides iturin A and surfactin (Figure 2).
Cyclosporin A is commonly used in topical antibiotics
to promote faster healing and is also a potent immuno-
suppressant widely used to prevent rejection of trans-
planted organs [51]. Valinomycin and enniatins such as
enniatin A1 are, like cyclosporin A, common potent
antiobiotics and are also depsipetides. The enniatins are
a class of cyclic peptides with alternating D,L residues
which are currently of great interest for the develop-
ment of new antibiotics and other pharmaceuticals [52,
53]. Iturin A and surfactin are lipopeptides (i.e., con-
taining a fatty acid residue), that exhibit biosurfactant
and antibiotic properties. They are powerful antifungal
agents produced naturally by Bacillus subtilis, and as
such are used as easily biodegradable pesticides [8].
In the present study, the CAD patterns of the pro-
tonated and metal-cationized peptides (Ag, Mn2,
Ni2, Pb2, Co2, K, Na, Li, Sr2, and Ca2) are
compared. It is shown that the diagnostic utility of the
fragmentation information of the metal complexes is
metal specific. Of all the metal ions tested, those which
provide the most useful complementary structural in-
formation to that of the protonated peptides are Na
and Pb2 ions for the depsipeptides, and Ni2, Sr2,
Ag and Li for the other cyclic peptides.
Experimental
All mass spectrometry experiments were performed
with a ThermoQuest LCQ quadrupole ion trap mass
spectrometer (ThermoFinnigan, San Jose, CA) operated
ipeptides (b) valinomycin and (c) enniatin A1.
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heated-capillary temperature of 125 °C. The Harvard
syringe pump system (Harvard Apparatus Inc., Hollis-
ton, MA) was operated at a flow rate of 4 l/min for all
experiments. Lens voltages were set for all experiments
by auto-tuning the LCQ on the ion of interest. Solution
containing 2.5 to 10 M of the peptide and 2% glacial
acetic acid in methanol were used for studies of proton-
ated peptide. The same concentration of peptide with a
20-fold excess of a metal ion in methanol with no acid
added was used for studies of metal ion complexes. For
studies of the metal complexes, sheath flow gas (N2)
was set at 20 arbitrary units. For studies of protonated
peptides, no sheath gas was used because signal inten-
sities were greater without the sheath gas. The ion
trap was operated at a nominal pressure of 1  105
torr of He. Spectra presented in this study are an
average of 1000 scans. All metal salts used for these
experiments were purchased from Aldrich Chemical
Co. (Milwaukee, WI) and used without further puri-
fication. Cyclosporin A was obtained from Calbio-
chem (La Jolla, CA). Surfactin, iturin A, valinomycin,
and enniatin A1 were obtained from Sigma (Milwau-
kee, WI). The methanol was Certified A.C.S. Spec-
Figure 2. Structures of lipopeptides (a) anteiso-iturin A and (b)
iso-surfactin C1.tranalyzed grade from Fisher Scientific (Pittsburg,
PA).
Nomenclature for Labeling the Fragment Ions
Fragment ions are labeled according to a slight varia-
tion of the descriptor system developed by Ngoka and
Gross [54]. An ion is labeled as xm
n
J/Z, where “x” is the
designation for the ion (“a” to “c” or “x” to “z”, lower
case). Thus, a “b” ion is likely to be either a five-member
oxazolone ring, or a six-member aziridinone ring with
two ketone groups [55]. Aziridinone ring formation has
also been shown to be likely in the special case of
residue loss next to a proline, where the oxazolone ring
would be strained, or in metal-directed cleavage. Ox-
azalone ring formation is more likely for the cleavage of
a peptide bond not involving a proline and non-metal-
directed cleavages. These “b” ion species may lose a
carbon monoxide to form an “a” ion. The term “m” is
the number of amino acid residues in the ion, “n” is the
ion’s charge, and “J” and “Z” are the single letter (upper
case) codes for the two amino acid residues connecting
the backbone amide bond J™Z that was broken to form
the decomposing linear oxazalone ion or isomeric
equivalent. A possible CAD reaction pathway for for-
mation of “b” and “y” ions is shown in Scheme 1,
involving an oxazolone intermediate along with loss of
a residue in an aziridinone form, leaving the C-terminal
end as an oxazolone group and the N-terminal end as
an amine [55]. The objective of the nomenclature sys-
tem, however, is to classify product ions and not to
indicate their origins [33]. Also, as indicated in Scheme
1, the designated site of “ring opening” is the site of
backbone cleavage that converts the cyclic peptide into
a linearized peptide and from which “a” to “c” and “x”
to “z” ion designations are derived. Use of the term
“cleavage” not preceded by “ring” refers to backbone
cleavages of the linearized peptide. Appendix I is
included at the end of this work which gives abbrevia-
tions for all residues and residue moieties relevant to
this work.
A few variations were made to the descriptor system
of Ngoka and Gross for special considerations of the
data in this study. The ion’s charge, “n”, is included to
differentiate between the singly and doubly charged
fragment ions observed. A backslash (/) is added for
consistency for occasional occurrences when the same
two adjacent residues occur more than once in a cyclic
peptide amongst non-identical surrounding residues. In
such cases, the residue sequence subscript (i.e., J/Z) is
extended to include one unidentical residue so that the
subscript refers to one unique location in the peptide
sequence (e.g., xm
n
J/ZU). Since in the MS
n data presented
herein the cation is always attached to the peptide when
these labels are used, for simplicity, the metal ion or
proton is omitted from the labels whether a proton or
metal ion is bound to the peptide. Thus, for MSn of a
singly protonated peptide, “b” and “y” designations
refer to (peptide  i residues  H) ions, where i is the
ons a
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designations refer to (peptide  i residues  2H),
(peptide i residuesmetal(I)), (peptide i residues
 metal(II))2 and (peptide  i residues  metal(II) 
H) ions for MSn of doubly protonated peptide, singly
charged monovalent metal cationized peptide, doubly
charged divalent metal cationized peptide, and singly
charged divalent metal cationized peptide, respectively.
For those product ions where it is indeterminate
whether residue increments are increasingly lost in the
amine to carbonyl direction, producing “x” to “z” type
ions, or in the carbonyl to amine direction, producing
“a” to “c” ions, a “long-hand” notation is used to
describe the ion structure. For example, (CSA  Na 
A) and (CSANA V) indicate fragment ions of
sodium cationized cyclosporin A that have lost an A
residue and the non-adjacent A and V residues, respec-
tively. Since one can not unequivocally classify such
ions as “a” to “c” or “x” to “z” type ions, fragment ions
for which the direction of increasing residue loss, and
hence the “a” to “c” or “x” to “z” designations, are
indeterminate are listed in the tables in the columns
headed “indeterminate ions”.
Results and Discussion
For each of the five cyclic peptides in this study,
solutions were prepared containing one of the metal
Scheme 1. Formation of b J/Z and y

J/Z iions (typically at 50 to 200 M) and one of the cyclic
peptides at a 20-fold lower concentration (2.5 to 10 M).
This work focuses on those metal ions that have the
most potential for providing complementary informa-
tion for peptide structure characterization compared
with that obtained for the protonated peptides. The
peptide complexes containing Ag, Ni2, Pb2, Co2,
K, Na, Li, Sr2, and Ca2 ions were evaluated in
greater detail. Complexes of the cyclic peptide with
other metal ions, including Cs, Rb, Mg2, Mn2,
Fe2, Cu2, and Zn2, were also investigated in prelim-
inary studies. However, CAD of the Cs and Rb
complexes resulted in poor signal intensity of the prod-
uct ion spectra because the metal ion was lost, resulting
in the neutral peptide. On the other hand, CAD of
complexes of cyclic peptides with Mg2, Mn2, Fe2,
Cu2, and Zn2 resulted in fragmentation that was too
extensive to be analytically useful for sequence deter-
mination, so these metal ions were not included in
further experiments.
Many of the metal complexes of cyclosporin A
formed by ESI have greater intensities than protonated
cyclosporin A. Figure 3 shows the ESI mass spectra
obtained for cyclosporin A in the protonation mode and
with metal cationization using AgNO3 as the metal salt.
The intensity of the (cyclosporin A  Ag) complex in
Figure 3b is fourteen-fold greater than that of proton-
ated cyclosporin A in Figure 3a. The signal intensities
nd peptide fragment ion label designations.
31043J Am Soc Mass Spectrom 2004, 15, 1039–1054 MSn CHARACTERIZATION OF CYCLIC PEPTIDESobtained for the various metal complexes relative to the
protonated peptides are summarized in Table 1 to
indicate the complexes which provide the greatest rel-
ative sensitivities. Complexes with two monovalent
ions were occasionally observed for the solutions con-
taining lithium, sodium or silver. For solutions contain-
ing divalent metal ions, (peptide  metal(II)  counte-
rion) ions were often observed along with (peptide 
metal(II)  H) species.
After electrospray ionization (ESI), singly charged
[peptide  metal(I)] or [peptide  metal(II)  H]
complexes and, if observed, the doubly charged [pep-
tide  2 metal(I)]2 or [peptide  metal(II)]2 com-
plexes were isolated and subjected to MSn analysis. The
CAD experiments were conducted so that one to five
percent of the precursor ion remained in the product
spectra. The CAD results for protonated cyclosporin A
and its metal complexes will be discussed in great detail
to illustrate the systematic analysis undertaken, then
the discussion of the other cyclic peptides will focus
only on the metal complexes that gave the CAD spectra
most useful for structural characterization relative to
the protonated peptides.
Cyclosporin A
The ESI mass spectra obtained for cyclosporin A (CSA)
are summarized in Table 1. Complexation with stron-
tium, calcium, and potassium ions resulted in the most
intense complexes relative to formation of protonated
Figure 3. ESI-mass spectra of (a) 50 M cyclosp
cyclosporin A in methanol with 200 M AgNOorin A in methanol with 2% acetic acid and (b) 5 M
.Table 1. Relative intensities of metal complexes and doubly
protonated cyclic peptides compared to singly protonated
peptidesa
Complexc
Cyclic peptide (CP)b
CSA VM EA IA SF
(CP  H) 100 100 100 100 100
(CP  2H)2 16 0 10 0 1
(CP  Li) 1800 25 560 465 205
(CP  2Li)2 810 25 0 110 0
(CP  Na) 2350 45 675 1600 195
(CP  2Na)2 1060 0 0 0 0
(CP  K) 3150 275 390 665 295
(CP  Ag) 1400 210 1700 115 780
(CP  2Ag)2 840 1 35 35 0
(CP  Ca  H) 1840 75c 120 65 695
(CP  Ca)2 4600 150 15 655 301
(CP  Sr  H) 630 40c 120 160 610
(CP  Sr)2 4750 85 5 535 1045
(CP  Co  H) 380 3c 95 135 565
(CP  Co)2 445 2 35 25 475
(CP  Ni H) 490 1c 70 110 685
(CP  Ni)2 1640 2 25 55 280
(CP  Pb H) 130 35 40 76 300
(CP  Pb)2 370 25 4 305 220
aAll values in a column represent the relative intensities of the specified
complex from metal containing solutions scaled to the intensity of the
protonated peptide (intensity  100) from an appropriate acidified
solution.
bCSA  cyclosporin A, VM  valinomycin, EA  enniatin A1, IA  iturin
A, SF  surfactin.
cThe intensity of the (peptidemetal(II) H) or (peptidemetal(II)
counterion) is used, whichever is most intense.
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acetic acid, as shown in Figure 3a, the ESI-mass spec-
trum is dominated by sodium complexes, and the
protonated peptide has only 20% relative abundance.
For the silver complexation experiment, as shown in
Figure 3b, (CSA  Ag) is the base peak with (CSA 
2Ag)2 at 60% relative abundance. For the solutions
containing alkali metal salts, the (CSA  metal) com-
plexes are dominant, with substantial (CSA  2 
metal)2 complexes for lithium and sodium. For cobalt,
nickel, lead, calcium, and strontium, the (CSA  met-
al[II])2 complexes are most intense ions.
The fragment ions observed in the MS2 and MS3
spectra of protonated and doubly protonated cyclo-
sporin A are shown in Table 2. In Table 3 are listed the
fragment ions observed upon CAD and MSn analysis of
nickel and lithium cationized cyclosporin A complexes.
Additional MSn data for other cyclosporin A/metal
complexes analyzed are provided in Supplementary
Tables S1–S3. (See Appendix II). Based on analysis of all
the CAD (MSn) spectra and compilation of the se-
quence-related fragment ions in Tables 2 and 3, snap-
shots of the dominant cleavages and diagnostic se-
quence information are presented in Scheme 2 in a
manner similar to that reported by Gross et al. [34].
The most easily interpretable mass spectra for deter-
mining the sequence of a cyclic peptide have a complete
series of “b” or “y” ions, allowing the masses of the
Table 2. MSn results for protonated cyclosporin Aa
(CSA  H)
MSn Precursor ion Indetermin
MS2 (CSA  H) (CSA  U)
MS3 (CSA  U) (CSA  U  m
(CSA  2H)2
MSn Precursor ion Indetermination
MS2 (CSA  2H)2 (CSA  2H  112)2
(CSA  2H  112  Z)
(CSA  H  112  Z)
(CSA  2H  112  Z
(CSA  H  112  Z 
(CSA  H  112  Z 
MS3 (CSA  2H  112)2 (CSA  2H  112  Z)
(CSA  2H  112  z
MS4 (CSA  2H  112  Z)2
MS3 (CSA  2H  112  Z
 CO)2
aCSA  cyclosporin A; U  N-methyl valine; Z  N-methyl leucine; J 
 side chain of J; C7H12O; mNH2  methyl amine.residues in the peptide to be determined sequentially in
a residue-by-residue fashion. The presence of addi-
tional “a”, “c”, “x”, and “z” ions may further confirm
that the ions tentatively designated as “b” and “y” ions
are indeed correct. Furthermore, “c” or “z” ions with
masses that differ from the corresponding “b” or “y”
ions, respectively, by additions or losses of 31 Da or 17
Da can verify whether the residue is an unmodified
residue with an unmethylated backbone amine (17 
NH3) or an N-methylated residue (31  N-methyl
amine). For instance, the (CSAH 112 Z) (where
Z  N-methyl leucine) and (CSA  H  112 
ZmNH2)
 ions in the CAD spectrum of (CSA 
2H)2, listed in Table 2, indicate that the Z residue lost
has a methylated backbone nitrogen. Likewise, the
b8

U/J and c8

U/J ions, separated by 31 Da, in the MS
3
spectrum of (CSA  Ni)2, listed in Table 3, indicate
that the terminal residue of the lost tripeptide (Z) has a
methylated backbone nitrogen. Together, the data from
both spectra indicate that the two adjacent residues
with masses of 127 Da both contain methylated back-
bone nitrogens, identifying them as ZZ. Identification of
other “c” or “x” ions provide more information on
locations of methylated backbone nitrogens. This type
of analysis is used throughout the present study to
assist in identification of unusual or modified residues.
As can been seen in Table 2, protonated cyclosporin
A gives little sequence information and produces very
Fragment ions
ons a, b, & c ions x, y & z ions other
(b6Z/V  H)

2)
 a9

U/J, b6

U/J
Fragment ions
a, b, & c ions x, y, & z ions other
(y9  2H)

Z/U (Z  )
,
y5

Z/U (ZAA  H)

)2
)
H2)

(y7  CO)

Z/U (Z  )
,
)2 (y8  2H)

Z/U (ZAA  H)

(y7  H)

Z/U
(b9  112)
2
Z/U (Z  )

(b7  112)
2
Z/U (ZAAH)

(b9112)

Z/U
(b7112)

Z/U
(b6112)

Z/U
(Z  )
(ZAA  H)
4[(E)-2-butenyl]-4-methyl-L-threonine;   2-amino-butanoic acid; 112ate i
NH
ions
2
 CO
CO
mN
2
 CO
4(R)-
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could be obtained for (CSA  H) because of the rapid
loss of the signal intensity in the CAD spectra. MSn
experiments of the (CSA  2H)2 ion yielded no simple
“b” or “y” ions and instead resulted in some ambiguous
fragment ions. The MSn experiments resulted in (CSA
H  U) ion (which could be designated as either a
b10

U/J or y10

Z/U ion, and is an indeterminate fragment
ion), and a9

U/J and b6

U/J ions. For example, (CSA 
2H)2 produced an equivocal fragment ion via loss of
112 Da, probably due to loss of part of the side chain of
the J residue. This type of fragment ion is problematic
because it can be mistaken for the loss of an entire
residue. The loss of the side-chain of J is also isobaric
with loss of (U  H). All of the expected “a”, “b”, and
“c” ions, which are produced in the MS2 to MS4
experiments, are consequently shifted by 112 Da, such
as (CSA  U  112)2 [which could be designated as
either a (b10  112)
2
U/J or (y10  112)
2 ion], and (c9 
112)2U/J, among others. All the y-type ions produced
in the MS2 to MS3 experiments are also shifted by 2 Da,
Table 3. MSn results for cyclosporin A complexes containing N
(CSA  Ni-H)
MS2n Precurser ion Indeterminate ions
MS2 (CSA  Ni  H) (CSA  Ni  H  112)
MS3 (CSA  Ni  H  112) (CSA  Ni  H  112  Z)
(CSA  Ni  H  112  Z 
MS4 (CSA  Ni  H  112  Z) (CSA  Ni  H  112  Z 
(CSA  Ni)2
MSn Precursor ion Indeterminate i
MS2 (CSA  Ni)2 (CSA  Ni  H2O)
2
(CSA  Ni  CO)2
(CSA  Ni  U)2
MS3 (CSA  Ni  U)2 (CSA  Ni  U  CO)2
MS4 b9
2
U/J b8
2
U/J, b8

U/J, (b8  CO
MS5 b8
2
U/J
(CSA  Li)
MSn Precursor ion Indeterminate
MS2 (CSA  Li) (CSA  Li  112)
(CSA  Li  112  CO
MS3 (CSA  Li  112) (CSA  Li  112  Z 
(CSA  Li  112  Z)
MS4 (CSA  Li  112  CO) (CSA  Li  112  Z 
aCSA  cyclosporin A; U  N-methyl valine; Z  N-methyl leucine; J 
 side chain of J; C7H12O; mNH2  methyl amine.likely due to a dehydrogenation reaction. The peptide
backbone cleavages corresponding to the formation of
“a” to “c” and “y” ions are depicted in Scheme 2a. From
the collection of fragment ions obtained in the CAD
spectra (MS2 and MS3) of protonated and doubly pro-
tonated cyclosporin A, at most only the ZZU sequence
and the presence of  can be determined, as illustrated
by the peptide sequence coverage in Scheme 2a.
MSn analysis indicates that several metal cationized
complexes of cyclosporin A facilitate the determination
of a greater portion of the peptide sequence compared
with MSn analysis of protonated cyclosporin A. For
cyclosporin A, the nickel and lithium complexes pro-
vided the most extensive sequence information. For
(CSA  Ni)2, with MSn results shown in Table 3, the
percentage of simple “b” or “y” ions is much greater
than for doubly protonated cyclosporin A. From the
MS3 and MS4 spectra, stemming from (CSA  Ni 
U)2 and b9
2
U/J precursor ions, respectively, one or two
“b” ions are dominant in each spectrum, each the result
of the loss of one or two residues from the selected
d Lia
Fragment ions
a, b, & c ions x, y, & z ions

H2)
 (b9112  mNH2)

Z/U (y9  2H)

Z/U,
(b9  112  Z)

Z/U (y8  2H  H2O)

Z/U
(b9  112  Z  mNH2)

Z/U (y7  H  H2O)

Z/U
(a9  112  Z  mNH2)

Z/U (y7  H CO  H2O)

Z/U
Fragment ions
a, b, & c ions
(b9
2
U/J, a9
2
U/J, C8

U/J, b8

U/J (b8  mNH2)

U/J
b9
2
U/J, a9
2
U/J, b8
2
U/J
c8

U/J, b8

U/J b6

U/J (b8  mNH2)

U/J
C8

WH
a8
2
U/J, b7
2
U/J, b6
2
U/J
Fragment ions
a, b, & c ions

 (b8  CO)

U/J, b7

U/J
(b7  CO)

U/J, b5

U/J a5

U/J, b4

U/J
(b4  CO)

U/J, (b3  CO)

U/J
4[(E)-2-butenyl)]-4-methyl-L-threonine;   2-amino-butanoic acid; 112i2 an
CO)
mN
ons
)U/J
ions
)
CO)
CO)
4(R)-
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sponding to the b6
2
U/J and b7
2
U/J ions are key frag-
ments. Along with the b8

U/J and b6

U/J ions in the MS
3
and MS4 spectra and the doubly charged “b” ions, five
sequentially arranged residues are easily identified
from (CSANi U)2 (a.k.a. b10
2
U/J or y10
2
Z/U), b9
2
U/J,
b8
2
U/J, b7
2
U/J, and b6
2
U/J ions). The peptide backbone
cleavages corresponding to the “a” to “c” and “y” ion
formations are depicted in Scheme 2b. The determined
sequence from this data is AAZZU, as illustrated by the
peptide sequence coverage in Scheme 2b. This is more
sequence information than was obtained from both
protonated and doubly protonated cyclosporin A.
For MSn analysis of (CSA  Li) (Table 3), simple
“b” or “y” ions are not observed in the MS2 and MS3
spectra. In the MS2 spectrum for (CSA  Li), only
(CSA  Li  112) and (CSA  Li  112  CO) ions
are observed, and for the MS3 spectrum, (CSA  Li 
112  Z  CO) and (CSA  Li  112  Z) ions are
present. However, in the MS4 spectrum, b7

U/J, b5

U/J,
a5

U/J and b4

U/J ions are present, with their formation
due to the backbone cleavages presented in Scheme 2c.
Combining this data with that obtained from doubly
protonated and nickel cationized cyclosporin A, seven
of the eleven cyclosporin A residues could be identified
in order: VZAAZZU, which leaves only the JZ
segment undetermined.
MSn results of cyclosporin A complexes containing
other metal ions, including Na, K, Ag, Sr2, Ca2,
Co2, and Pb2, are provided in Supplementary Tables
Scheme 2. Product ions formed by MSn of (a) protonated and (b)
lithium and (c) nickel cationized cyclosporin A. An asterisk
indicates site of ring cleavage. The MSn labels above cleavage lines
indicate the round of MSn in which the resulting ion had the
greatest relative abundance in the mass spectrum.S1–S3. MSn experiments for (CSA  Na) and (CSA 
K) complexes resulted in product ions similar to those
obtained for MSn of (CSA 2H)2, except that no “x” to
“z” ions and not as many as “a” to “c” ions were
produced (Table S1). MSn analysis of (CSA  Ag)
(Table S2), resulted in abundant production of “y” ions
and unique “x” ions, indicating the presence of back-
bone amine groups on both termini of the fragment ion.
The J and  residues remain coordinated to the silver
ion despite loss of several surrounding residues, per-
haps because of polar hydroxyl group on the J residue.
The results for MSn for (CSA  Ca)2 and (CSA  Sr)2
complexes (Table S2) were also similar to those ob-
tained for (CSA  2H)2, although fewer “a” to “c” and
“x” to “z” ions were produced and most of the “b” and
“y” ions had additional CO or methylamine units
attached, indicating peptide fragment ions with either
amine or carbonyl groups at both termini. The results
for MSn of both cobalt cationized cyclosporin A com-
plexes, (CSA  Co)2 and (CSA  Co  H) ions,
(Table S3), were similar to those for (CSA  Ca)2 and
(CSA  Sr)2, except for the production of several “a”
ions. For MSn of (CSA  Pb  H) and (CSA  Pb)2
ions, very few diagnostic fragment ions were produced
(Table S3).
From the sequence information obtained by analyz-
ing the MSn data for each of the cyclosporin A com-
plexes, the lithium and nickel complexes provide the
most complete sequence coverage.
Depsipeptides: Valinomycin and Enniatin A1
Valinomycin. For valinomycin (VM) and the other re-
maining peptides, only the metal complexes that give
the most diagnostic sequence information are discussed
in detail, with an emphasis on comparison to the
information obtained from the protonated peptides.
The ESI mass spectra obtained for solutions containing
valinomycin (VM) are summarized in Table 1. Compl-
exation with potassium or silver ions resulted in the
most intense complexes relative to formation of proton-
ated cyclosporin A, and all of the metal salts resulted in
peptide complexes that were sufficiently intense for
CAD analysis. The spectra for solutions containing the
divalent metal ions showed significant interferences
from complexation of valinomycin with adventitious
potassium, sodium, and water-adducted protonated
valinomycin, yet both the (VM  metal[II]  H) and
(VM  metal[II]) complexes always had intensities of
at least 50 to 100% relative abundance.
From MSn analysis, the sequence of valinomycin that
could be deciphered was much greater for combined
analysis of the lead and sodium or lithium metal
complexes than for protonated valinomycin. The dom-
inant protonated species in the ESI-mass spectrum for
the acidified solution of valinomycin (abbreviated VM)
in methanol is a water adduct, (VM  H  H2O)
,
which simply dehydrates upon collisional activation.
The resulting (VM  H) species primarily loses CO
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 H  CO) ion in the MS4 experiment yields sequence
ions involving various two residue losses from the
precursor ion (data not shown). Because of the complex-
ity of the spectrum, the lack of a product ion due to a
single residue loss, and the low relative intensities of
most of the fragment ions, further rounds of MSn were
not fruitful. Scheme 3a summarizes the cleavages ob-
served from the MSn analysis of protonated valinomycin.
A summary of the results of MSn experiments from
n  2 to 10 for the (valinomycin  Na) complex are
included in Scheme 3b (supplemental Table S4). For the
first round of CAD on the sodium complex, the domi-
nant pathway is the loss of a single lactic acid residue.
The next three most dominant ions are due to losses of
one or two residues. In additional rounds of MSn from
n  3 to 10, the spectra become even more simple, and
for n  4 to 10, only one or two fragment ions are
present with one always due to the loss of an additional
residue in the correct sequence. Whether the fragments
are b-type or y-type ions can be determined from the
surrounding ions due to losses of or retention of NH3,
H2O, and CO. CAD of the (VM  Na  V)
 ion
produces a dominant (VM  Na  VX) ion (a.k.a.
y10

/V) in the MS
4 spectrum, and in the MS5 and MS6
spectra, dominant (VM  Na  VXV) (a.k.a. y )
Scheme 3. Product ions formed by MSn of (a) protonated and (b)
sodium and (c) lead cationized valinomycin. Lines between letters
represent peptide backbone cleavages (both the “ring cleavage”
that linearizes the cyclic peptide and other “cleavages” resulting
in loss of residues. An asterisk indicates site of ring cleavage. The
MSn labels above cleavage lines indicate the round of MSn in
which the resulting ion had the greatest relative abundance in the
mass spectrum. A dagger symbol indicates an out of sequence
residue loss.9 /Vand (VM  Na  VXV) (a.k.a. y8

/V) ions, respec-
tively, are observed.
By sequential elimination of one residue at a time
from the sodium-cationized valinomycin, a total of nine
residues in sequence can be determined. In the MS10
spectrum, the only product ion observed is the (VX 
Na) ion. This data is similar to that obtained by Gross
and co-workers for the (VM  Li) complex [34]. MSn
of lithium cationized valinomycin resulted in sequential
elimination of residues with each cycle of MSn, with n
1–10, after ring opening at the lactone bond, produc-
ing a series of b11

V/ through b3

V/ ions. MS
n analysis
of (VM  K) was not as useful because this complex
simply disassembled to a greater extent than the so-
dium or lithium cationized valinomycin, releasing the
neutral peptide.
MSn analysis of valinomycin complexes containing
divalent alkaline earth metal ions and transition metal
ions such as nickel(II), cobalt(II), and lead(II) predomi-
nantly effect losses in increments of two residue units.
Thus, as shown in Scheme 3c for MS2 through MS5 of
(VM  Pb  H) ions, residues are lost in larger
increments than for the alkali metal or protonated
complexes, producing fewer fragment ions, but provid-
ing coverage of the entire valinomycin sequence. By
comparison of the MSn data for sodium and lead
complexes, residues can be identified that could not be
mapped from the MSn experiments with lithium and
sodium cationized valinomycin. Unfortunately, when
only the last two or three residues of the peptide
remain, the residue loss often does not continue in the
same order; instead residues from the opposite end of
the peptide fragment are lost. Thus, it was determined
that for depsipeptides such as valinomycin, as well as
for enniatin A1, as will be discussed below, the identity,
but not the complete sequence can be determined with
a high degree of certainty. Another caveat with the
analysis of the MSn spectra of valinomycin with diva-
lent metal ions is that the cleavages are either “c” or “x”
ions, with cleavage only at the ester bonds.
The MSn experiments of (VM SrH) and (VM
Ca  H) ions also predominantly result in losses of
two residues at a time until only two residues: V,
ultimately remain complexed to the metal ion. MS2
spectra for (VM  Ag) were similar to those observed
for the alkali metal complexes, but extensive fragmen-
tation produced dozens of ions present with signal
intensities of 5–10% relative abundance which do not
correspond to “a” to “c” or “x” to “z” ions, thus
obscuring the information obtained from the spectrum.
From the sequence information that can be obtained
for MSn of each of the protonated or metal-cationized
valinomycin ions, MSn of lithium-cationized and sodi-
um-cationized valinomycin produce the greatest se-
quence coverage (nine residues in sequential order in
nine CAD cycles). MSn of lead-cationized and stron-
tium-cationized valinomycin provide complete residue
analysis in six CAD cycles, which if used in combina-
tion with the lithium or sodium complex data, can
1048 WILLIAMS AND BRODBELT J Am Soc Mass Spectrom 2004, 15, 1039–1054provide total sequence coverage and masses of all
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Enniatin A1. Sodium and silver cationized enniatin A1
(EA) produced the most intense signals relative to
protonated enniatin A1 in the ESI mass spectra, as
indicated in Table 1. The only protonated complex in
the ESI-mass spectrum of enniatin A1 (abbreviated EA)
was a water adduct, while sodium and potassium
complexes otherwise dominated the ESI-mass spec-
trum, as they did for valinomycin. MSn experiments
were undertaken for all of the various metal complexes
and protonated enniatin A1, but only the ions that gave
the most diagnostic CAD spectra are discussed in detail.
These ions include the sodium and lead complexes.
The results for MSn experiments performed on pro-
tonated enniatin A1 (the water adduct) and the sodium
and lead complexes of enniatin A1 of the form (EA 
Na) and (EA  Pb  H) reveal key differences
(supplemental Table S5). The loss of the water was the
only significant reaction upon collisional activation of
(EA  H3O)
. Only two additional rounds of CAD
were fruitful for analysis of (EA  H). For the MS3
experiment, loss of Z, U, ZX, and ZU was observed,
along with (ZX  H), (ZX  OH), (UX  H) and
(UX  OH) ions. CAD of the (EA  H  U) ion
resulted in a dominant (EAH U Z) ion with the
(EA  H  UX) ion at 15% relative abundance. CAD
of the (EA  H  Z) ion resulted in three main
fragment ions: (EAH Z Z), (EAH ZU)
and (EA  H  ZX), with the last having the correct
sequence order but the lowest intensity.
For the sodium-cationized enniatin A1 complex, the
fragmentation routes simplify with increasing rounds
of MSn, thus giving the most useful sequence informa-
tion overall. Since there are only six residues in enniatin
A1, sequential rounds of MS
n can be conducted for each
individual residue loss from the precursor ion. By this
method, the sequence of the first four residues can be
correctly determined for the sodium complex. How-
ever, when only two residues remain, the sodium ion is
lost in conjunction with H2O and CO, and the last
remaining residue ion is out of sequence order. Al-
though the identities of the last two residues can be
narrowed down and speculated from the final data set,
the masses of the last two separate residues are not
directly obtained.
MSn analysis of the lithium ion complex of enniatin
A1 was similar to the analysis obtained for the sodium
complex, but the higher charge density of the lithium
ion caused water adduction during isolation and trap-
ping. For larger alkali ions such as potassium and
rubidium, much poorer signal intensities for fragment
ions were obtained, presumably due to disassembly of
the complex and loss of the neutral peptide. This
observation was common to the complexes containing
valinomycin with larger alkali metals as well as other
cyclic peptides studied.Lead complexes showed preferential loss of two
residues from the precursor ion (EA  Pb  H),
leaving the c/x ions (XZXZ  Pb  OH), and the
isobaric (XUXZ PbOH) and (XZXU PbOH)
ions. Beyond this double residue loss, additional neu-
tral losses occurred in one-residue increments down to
(XZ PbOH) and (XU PbOH). CAD of these
last ions produced (Z PbOHH2O)
 and (U Pb
 OH  H2O)
 via reactions of adventitious water
molecules in the ion trap. CAD of the (XZX  Pb 
OH) or (XUX  Pb  OH) ions resulted in incremen-
tal losses of residues corresponding to the correct
sequential order (X as well as XZ and XU).
Compared with the lead-cationized enniatin A1 com-
plexes, complexes with metal ions with higher charge
densities such as calcium, strontium, nickel(II), and
cobalt(II) showed extensive water adduct formation
after loss of the first two residues, XL or XU, so those
complexes gave little useful structural information.
Complexes of enniatin A1 with silver showed problems
similar to those with (VM  Ag), namely, overly
extensive fragmentation which obscured the identifica-
tion of product ions.
From the sequence information that was obtained for
MSn analysis of each protonated or metal-cationized
enniatin A1 species, protonated enniatin A1 loses resi-
dues in a non-sequential order, even for the first two
residues lost. Four residues can be determined in the
correct sequential order based on MSn analysis of
lithium- and sodium-cationized enniatin A1, and four
individual residues and one dipeptide segment can be
identified from the MSn spectra of lead-cationized en-
niatin A1.
Lipopeptides: Iturin A and Surfactin
Iturin A. The ESI mass spectra for solutions of iturin A
(IA) with metal salts are dominated by (iturin A 
metal) complexes for the alkali metals and silver, or
(iturin A  metal(II))2 and (iturin A  metal(II)  H)
ions for the divalent metals. The sodium, potassium and
calcium complexes are the most intense, and many of
the metal complexes have greater relative intensities
than protonated iturin A (Table 1). MSn analysis was
undertaken on each of the metal complexes. Only the
CAD spectra of the species that gave the most informa-
tive sequence information, in this case the silver and
strontium complexes relative to protonated iturin A, are
discussed in detail (Supplemental Table S6).
Figure 4 compares CAD spectra for protonated iturin
A and the (IA  Ag) and (IA  Sr  H) complexes.
The absolute intensities of the MS2 spectra are similar:
2.2  105, 1.57  105, and 2.84  105 (arbitrary units) for
Figures 4a, b, and c, respectively.
MSn of (IA  H) provides (IA H  Q) (a.k.a.
b7

Q/P or y7

N/Q), b6

Q/P, b5

Q/P, (IA  H  N)
 (a.k.a.
b or y ), b to b , (IA H  P) (a.k.a.7 Y/N 7 N/Y 6 N/S 2 N/S
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
P/N or y7

Q/P) and y6

Q/P to y5

Q/P ions, along with (b5
 P)Q/P, (b4-P)

Q/P, and (b4  PN)

Q/P internal
fragment ions. The cleavages that result in these ions
are depicted in Scheme 4a which summarizes the se-
quence coverage.
MSn experiments of (IA  Ag) provide (IA  Ag 
Q) (a.k.a. b7

Q/P or y7

N/Q) and b6

Q/P to b4

Q/P ions,
along with a b2

Q/P ion, (IA Ag  Y)
 (a.k.a. b7

Y/N or
y7

N/Y), and y6

N/Y to y5

N/Y ions. The MS
4 and MS5
spectra for (IA  Ag) are also quite simple. The
cleavages which result in these ions are depicted in
Scheme 4b.
MSn of the (IA  Sr  H) complexes provides the
most complete and accurate “y” ion sequence informa-
tion of all the iturin A complexes. The MSn experiments
for (IA  Sr  H) gave simple MS3 to MS5 spectra,
with (IA  Sr  2H  N) (a.k.a. (b7  H)

N/S or (y7 
H)P/N), y6

P/N to y2

P/N ions, along with a (y3 
N)N/S ion. In addition, the MS
n experiments with
strontium are the only ones to directly provide the mass
of the lipid residue of 239 Da as one of the neutral losses
(between y6

P/N and y5

P/N). These sequence results are
summarized in Scheme 4c.
Combining the MSn data from any two of these three
types of iturin A ions (i.e., protonated, (IA  Ag), and
(IA  Sr  H)) can provide complete sequence cover-
Figure 4. MS2 spectra for complexes of (a) (itu
 H). IA  iturin A. An asterisk identifies theage with generous overlap, simple b and y ions, and
greater certainty because of the more intense diagnostic
ions from the metal complexes. Combining all three
data sets provides even greater sequence confirmation.
The CAD results for the lead complex, (IA  Pb 
H), showed a very intense (IA  Pb  H  P) ion,
but MS3 of this ion was not informative. The only other
major diagnostic ion in the CAD spectrum for the lead
complex was a b6

P/N ion. MS
3 of the b6

P/N ion pro-
vided b5

P/N and b4

P/N ions. Other divalent metal ion
complexes produced MSn fragmentation similar to
those for lead or strontium complexes, but diagnostic
product ions were never over 10% relative abundance.
MS3 of the z7

Q/P ion for the alkali metal cationized
iturin A provided sequence information that was out of
order, indicating the residue order QNPS, rather than
the correct QPNS order.
Surfactin. In the discussion of MSn analysis of surfac-
tin complexes which follows, three letters are used to
designate the region of the site of ring opening and the
backslash (/) indicates the ring opening site itself. This
method of designation is followed here for surfactin
(SF) because there are two locations with two adjacent
leucines which must be differentiated. The Greek letter
“” is used to represent the “3-hydroxy-13-methyl
 H), (b) (iturin A  Ag), (c) (iturin A  Sr
ursor ion.rin A
prec
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the other amino acids are assigned their standard letter.
In the ESI mass spectra for solutions of surfactin with
metal salts, all of the metal complexes had greater
relative intensities than protonated surfactin (see Table
1). Moreover, the most sensitive and diagnostically
useful MSn spectra were obtained for the silver- and
nickel-cationized surfactin species, more so than for
protonated surfactin. Fragmentation of protonated sur-
factin, as listed in Table 4, provided good sequence
coverage from (SF  H  L) (a.k.a. b7

L/E or y7

L/L)
to b4

L/E and (SF  H  L)
 (a.k.a. b7

L/E or y7

L/L)
to y3

L/L ions (the six-residue “y” ion is a (y6 
2H)L/L ion), along with an analogous series of (SF 
H  L) to b5

L/L ions with water loss. This covers the
entire sequence of the cyclic peptide. However, only the
(SF  H  L), (y6  2H)

L/L and b4

L/L ions had
intensities greater than 5% relative abundance, thus
limiting the usability of the method for low peptide
concentrations.
(SF  Ag), (SF  Ni)2, and (SF  Pb)2 yield CAD
spectra with much greater relative abundances of sev-
eral of important fragment ions than the protonated
peptide spectra (see Table 4). MSn of (SF  Ag)
provides intense (SF  Ag  L), (y  2H) ,
Scheme 4. Product ions formed by MSn of (a) protonated iturin,
(b) silver and (c) strontium complexed iturin A. Lines between
letters represent peptide backbone cleavages (both the “ring
cleavage” that linearizes the cyclic peptide and other “cleavages”
resulting in loss of residues. An asterisk indicates site of ring
cleavage. The MSn labels above cleavage lines indicate the round
of MSn in which the resulting ion had the greatest relative
abundance in the mass spectrum.6 L/Ly5

L/L, y4

L/L, and (b6  2H)

L/LV, b5

L/LV, and b4

L/LV
ions, as well as (SF  Ag  2L), (y5  2H)

D/LL,
y4

D/LL, and y3

D/LL ions. The CAD spectrum for (SF 
Ni)2 shows a (SF  Ni  L)2 (a.k.a. b7

L/L, y7

D/LL,
b7

E/LL, or y7

/EL) ion and (y6  2H)

L/L to y4

L/L
ions, all with intensities above 60% relative abundance.
The MSn data available for (SF  Pb)2 is roughly
equivalent to that obtained for protonated surfactin, yet
with greater ion intensities.
The doubly charged alkaline earth metal ion com-
plexes, (SF  Sr)2 and (SF  Ca)2, and the singly
charged alkali metal complexes, (SF  K), (SF  Na)
and (SF  Li), all provided MSn results which gave
complete sequence coverage of surfactin, but the prod-
uct ion signals were less intense than those for the
silver, nickel, and lead ion complexes.
MSn experiments undertaken for protonated surfac-
tin provide the greatest absolute sequence information
of all the various surfactin ions analyzed, but has
practical problems with interfering ions due to the low
relative intensities of many product ions. MSn analysis
of (SF  Ag), (SF  Ni)2, and (SF  Pb)2 ions
provides more limited sequence coverage, allowing
determination of five or six residues in the correct
sequential order, but yield product ions with greater
relative and absolute intensities. Also, the data from
MSn spectra obtained for the (SF  Sr  H), (SF  Ni
 H) and/or (SF  Pb  H) complexes can be used
to identify the correct nominal masses of the individual
 and E residues, while only the correct nominal mass
of the E segment can be determined from the MSn
analysis of the other metal-cationized and protonated
surfactin species.
Conclusions
Based on MSn examination of the fragmentation pat-
terns of complexes containing numerous different met-
als, it is apparent that a single type of metal complex
does not universally provide diagnostic CAD spectra.
Instead, a better strategy for structural characterization
of cyclic peptides involves MSn analysis of several types
of metal complexes, thus capitalizing on the different
coordination sites of the metals which promote activa-
tion and cleavage of different bonds in the peptides. For
cyclosporin A, nickel and lithium complexation pro-
vided improved sequence coverage in the MSn spectra
and simpler, more easily interpretable data than did
protonation. In the cases of valinomycin and enniatin
A1, sodium and lead complexation provided greater
sequence coverage. For the lipopeptides iturin A and
surfactin, silver complexation showed improvement in
sequence coverage and increased relative abundance of
important diagnostic product ions. Overall, the MSn
data obtained from complexes of cyclic peptides with
metal ions provided valuable complementary and often
superior information for identity and sequence deter-
mination of cyclic peptides compared with that ob-
1051J Am Soc Mass Spectrom 2004, 15, 1039–1054 MSn CHARACTERIZATION OF CYCLIC PEPTIDEStained from protonated peptides. It is possible that
additional complementary sequencing information
might be obtained by CAD experiments with other
types of tandem mass spectrometers.
Table 4. MSn results for analysis of (surfactin  H), (surfactin
(SH  H)
MSn
Precursor
ion Indeterminate ions a, b
MS2 (SF  H) (SF  H-L) b6

L/
b4

L/
(SF  H-L-H2O)
 (b6-H2
(SF-2H-E) (b5-H2
(a4-H2
(a3-H2
(a2-H2
MS3 (SF  H-L) b6

L/
b3

L/
MS4 y4

D/LL
MS3 (y6-2H)

L/L
MS4 y4

L/L
(SF  Ag)
MSn Precursor ion Indeterminate ions a,
MS2 (SF  Ag) (SF  Ag-L) (b6-
(SF  Ag-E-2H) b5L/
MS3 (SF  Ag-L) (SF  Ag-2L) (b6-
MS4 y4

D/LL
MS5 (y4-72)

D/LL
MS6 (L  L  Ag)
(SF  Ni)2
MSn Precursor ion Indeterminate io
MS2 (SF  Ni)2 (SF  Ni-H-L)
(SF  Ni-H-1L)
(SF-Ni-H-L)
(SF  Ni-3H-E)
MS3 (y6  2H)

L/L
(SF  Pb)2
MSn Precursor ion Indeterminat
MS2 (SF  Pb)2 (SF  Pb-L)2
(SF  Pb-H-L
(SF  Pb-2L)2
MS3 (y6  2H)

L/L
MS3 b5

L/LV/ y5

L/L
a  3-hydroxy-13-methyl tetradecanoic acid; SF  surfactin.Acknowledgments
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g), (surfactin  Ni)2 and (surfactin  Pb)2a
Fragment ions
ons x, y, & ions others
L/E
L/E
(y62H)

L/L
y5

L/L
E
E
E
L/E y6

D/LL, y5

D/LL
y4

D/LL
y3

D/LL (y4-V)

D/LL
(y4-D)

D/LL
(L  L  H)
y5

L/L, y4

L/L
y3

L/L (y4-D)

L/L
(y4-V)

L/L
(L  L  H)
Fragment ions
c ions x, y, & z ions others
L/LV (y6  2H)

L/L

L/LV y5

L/L, y4

L/L
L/LV (y5  2H)

D/LL
y4

D/LL, y3

D/LL
(y4-72)

D/LL
(y4-y1  Ag)

D/LL (L  L  Ag)

(L  Ag  NH3  CO)

Fragment ions
a, b, & c ions x, y, & z ions
(b6-2H)

L/LV (y6  2H)

L/L, y5

L/L
(b6-2H)
2
L/LV
b5

L/LV
y5

L/L, y4

L/L
Fragment ions
s a, b, & c ions x, y, & z ions
(b6-2H)
2
L/LV (y6  2H)

L/L
(b6-2H)
2
L/LV y5

L/L, y4

L/L
b5

L/LV, b4

L/LV
y5

L/L, y4

L/L
b4

L/L, b3

L/L y4

L/L, y3

L/L A
, & i
E b5

E, b3

O)L/
O)L/
O)L/
)L/E
)L/L
E, b5

,
b, &
1H)
LV b4
2H)
ns
e ion
)

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Residue Abbreviation Key
Standard residues:
A  alanine (71 Da)
D  aspartic acid (115 Da)
E  glutamic acid (129 Da)
F  phenylalaine (147 Da)
G  glycine (57 da)
I  isoleucine (113 Da)
K  lysine (128 Da)
L  leucine (113 Da)
N asparagine (156)
P  proline (97 Da)
Q glutamine (128 Da)
R  arginine (156 Da)
S  serine (87 Da)
V  valine (99 Da)
Y  tyrosine (163 Da)
Other residues:
U  N-methyl valine (113 Da)
Z  N-methyl leucine (127 Da) (Z  N-methyl iso-
leucine (127 Da) for enniatin A1)
X  hydroxy isovaline (100 Da)
J  4(R)-4[(E)-2-butenyl]-4-methyl-L-threonine (183
Da)
  2-amino-butanoic acid (85 Da)
  N-methyl glycine (aka sarcosine) (71 Da)
	 3-amino-12-methyl tetradecanoic acid, the fatty
acid residue on iturin A (239 Da)
  3-hydroxy-13-methyl tetradecanoic acid, the
fatty acid residue on surfactin (240 Da)
  Lactic acid (72 Da)
Other abbreviations:
mNH2  methyl amine
Appendix II
Supplemental Tables
Supplementary material available: Several additional
CAD data tables are available (Tables S1–S6). To request
a copy of the tables, please contact the JASMS editorial
office in St. Louis, MO.
Table S1. MSn results for cyclosporin A complex
containing Na and K.
Table S2. MSn results for cyclosporin A complexes
containing Ag, Sr2 and Ca2.Table S3. MS3 to MS4 results MSn results for cyclo-
sporin A complexes containing Co2 and Pb2.
Table S4. MSn results for valinomycin complexes
containing Na and Pb2.
Table S5. MSn results for protonated, sodium-cation-
ized, and lead-cationized enniatin A1.
Table S6. MSn results for analysis of protonated
iturin and (iturin AAg) and (iturin A  Sr 
H) complexes.
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